The tumor suppressor WT1 drives progenitor cell progression and epithelialization to prevent Wilms tumorigenesis in human kidney organoids.


Journal

Stem cell reports
ISSN: 2213-6711
Titre abrégé: Stem Cell Reports
Pays: United States
ID NLM: 101611300

Informations de publication

Date de publication:
14 09 2021
Historique:
received: 18 02 2021
revised: 30 07 2021
accepted: 30 07 2021
pubmed: 28 8 2021
medline: 11 3 2022
entrez: 27 8 2021
Statut: ppublish

Résumé

Wilms tumor is the most widespread kidney cancer in children and frequently associated with homozygous loss of the tumor suppressor WT1. Pediatric tumorigenesis is largely inaccessible in humans. Here, we develop a human kidney organoid model for Wilms tumor formation and show that deletion of WT1 during organoid development induces overgrowth of kidney progenitor cells at the expense of differentiating glomeruli and tubules. Functional and gene expression analyses demonstrate that absence of WT1 halts progenitor cell progression at a pre-epithelialized cell state and recapitulates the transcriptional changes detected in a subgroup of Wilms tumor patients with ectopic myogenesis. By "transplanting" WT1 mutant cells into wild-type kidney organoids, we find that their propagation requires an untransformed microenvironment. This work defines the role of WT1 in kidney progenitor cell progression and tumor suppression, and establishes human kidney organoids as a phenotypic model for pediatric tumorigenesis.

Identifiants

pubmed: 34450039
pii: S2213-6711(21)00389-1
doi: 10.1016/j.stemcr.2021.07.023
pmc: PMC8452534
pii:
doi:

Substances chimiques

WT1 Proteins 0
WT1 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2107-2117

Informations de copyright

Copyright © 2021 Friedrich Miescher Institute for Biomedical Research. Published by Elsevier Inc. All rights reserved.

Références

Development. 2017 Aug 15;144(16):2862-2872
pubmed: 28811308
Oncogene. 2020 Jan;39(4):849-861
pubmed: 31562394
J Am Soc Nephrol. 2015 Sep;26(9):2097-104
pubmed: 25636411
Cell Stem Cell. 2022 Jan 6;29(1):160-175.e7
pubmed: 34847364
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
Cancer Cell. 2014 Sep 8;26(3):319-330
pubmed: 25155756
Stem Cell Reports. 2017 Jul 11;9(1):279-291
pubmed: 28552604
Nat Commun. 2014 Jul 17;5:4444
pubmed: 25031030
Dev Cell. 2018 Jun 4;45(5):651-660.e4
pubmed: 29870722
Nat Genet. 1998 Jan;18(1):15-7
pubmed: 9425891
Nat Genet. 2017 Oct;49(10):1487-1494
pubmed: 28825729
PLoS Biol. 2019 Feb 21;17(2):e3000152
pubmed: 30789893
Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3972-7
pubmed: 9108089
EMBO Mol Med. 2017 Feb;9(2):137-153
pubmed: 28028012
Cell. 1993 Aug 27;74(4):679-91
pubmed: 8395349
Nat Biotechnol. 2015 Nov;33(11):1193-200
pubmed: 26458176
Dis Model Mech. 2018 Nov 16;11(11):
pubmed: 30459183
Dev Biol. 2006 Mar 15;291(2):325-39
pubmed: 16442091
N Engl J Med. 2016 Jan 14;374(2):135-45
pubmed: 26536169
Nat Commun. 2020 Mar 11;11(1):1310
pubmed: 32161258
Dev Cell. 2012 Jun 12;22(6):1191-207
pubmed: 22698282
Nat Rev Nephrol. 2019 Apr;15(4):240-251
pubmed: 30705419
Nature. 2013 Jul 4;499(7456):43-9
pubmed: 23792563
Stem Cell Reports. 2014 Jun 26;3(1):24-33
pubmed: 25068119
Dis Model Mech. 2015 Aug 1;8(8):903-17
pubmed: 26035382
Neoplasia. 2016 Feb;18(2):71-81
pubmed: 26936393
Neoplasia. 2012 Aug;14(8):742-56
pubmed: 22952427

Auteurs

Verena Waehle (V)

Friedrich Miescher Institute for Biomedical Research, 4058 Basel, Switzerland; Faculty of Sciences, University of Basel, 4003 Basel, Switzerland.

Rosemarie Ungricht (R)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland.

Philipp S Hoppe (PS)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland.

Joerg Betschinger (J)

Friedrich Miescher Institute for Biomedical Research, 4058 Basel, Switzerland. Electronic address: joerg.betschinger@fmi.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH